These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 14751085)

  • 1. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.
    Krieg AM
    Curr Oncol Rep; 2004 Mar; 6(2):88-95. PubMed ID: 14751085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
    Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
    J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunostimulatory Activities of CpG-Oligodeoxynucleotides in Teleosts: Toll-Like Receptors 9 and 21.
    Lai CY; Yu GY; Luo Y; Xiang R; Chuang TH
    Front Immunol; 2019; 10():179. PubMed ID: 30800129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptor signaling in anti-cancer immunity.
    Okamoto M; Sato M
    J Med Invest; 2003 Feb; 50(1-2):9-24. PubMed ID: 12630564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiinfective applications of toll-like receptor 9 agonists.
    Krieg AM
    Proc Am Thorac Soc; 2007 Jul; 4(3):289-94. PubMed ID: 17607015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
    Schetter C; Vollmer J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
    Roda JM; Parihar R; Carson WE
    J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.
    Hornung V; Rothenfusser S; Britsch S; Krug A; Jahrsdörfer B; Giese T; Endres S; Hartmann G
    J Immunol; 2002 May; 168(9):4531-7. PubMed ID: 11970999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA.
    McCluskie MJ; Krieg AM
    Curr Top Microbiol Immunol; 2006; 311():155-78. PubMed ID: 17048708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection.
    Chaput N; Schartz NE; André F; Taïeb J; Novault S; Bonnaventure P; Aubert N; Bernard J; Lemonnier F; Merad M; Adema G; Adams M; Ferrantini M; Carpentier AF; Escudier B; Tursz T; Angevin E; Zitvogel L
    J Immunol; 2004 Feb; 172(4):2137-46. PubMed ID: 14764679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides.
    Wilson HL; Dar A; Napper SK; Marianela Lopez A; Babiuk LA; Mutwiri GK
    Int Rev Immunol; 2006; 25(3-4):183-213. PubMed ID: 16818371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
    Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
    Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Toll-like receptor recognizes bacterial DNA.
    Hemmi H; Takeuchi O; Kawai T; Kaisho T; Sato S; Sanjo H; Matsumoto M; Hoshino K; Wagner H; Takeda K; Akira S
    Nature; 2000 Dec; 408(6813):740-5. PubMed ID: 11130078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses.
    Loré K; Betts MR; Brenchley JM; Kuruppu J; Khojasteh S; Perfetto S; Roederer M; Seder RA; Koup RA
    J Immunol; 2003 Oct; 171(8):4320-8. PubMed ID: 14530357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells.
    Vollmer J; Jurk M; Samulowitz U; Lipford G; Forsbach A; Wüllner M; Tluk S; Hartmann H; Kritzler A; Müller C; Schetter C; Krieg AM
    J Endotoxin Res; 2004; 10(6):431-8. PubMed ID: 15588427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments.
    Ahmad-Nejad P; Häcker H; Rutz M; Bauer S; Vabulas RM; Wagner H
    Eur J Immunol; 2002 Jul; 32(7):1958-68. PubMed ID: 12115616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Toll for lupus.
    Anders HJ
    Lupus; 2005; 14(6):417-22. PubMed ID: 16038103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Toll-like receptors in costimulating cytotoxic T cell responses.
    Schwarz K; Storni T; Manolova V; Didierlaurent A; Sirard JC; Röthlisberger P; Bachmann MF
    Eur J Immunol; 2003 Jun; 33(6):1465-70. PubMed ID: 12778463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of murine embryonic fibroblasts to define Toll-like receptor activation and specificity.
    Kurt-Jones EA; Sandor F; Ortiz Y; Bowen GN; Counter SL; Wang TC; Finberg RW
    J Endotoxin Res; 2004; 10(6):419-24. PubMed ID: 15588425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides.
    Klinman DM; Zeuner R; Yamada H; Gursel M; Currie D; Gursel I
    Ann N Y Acad Sci; 2003 Dec; 1002():112-23. PubMed ID: 14751829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.